Cara Therapeutic Revenue vs. Gross Profit
| CARA Stock | USD 5.12 0.08 1.59% |
For Cara Therapeutic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cara Therapeutic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cara Therapeutic utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cara Therapeutic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cara Therapeutic over time as well as its relative position and ranking within its peers.
Cara |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cara Therapeutic Gross Profit vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cara Therapeutic's current stock value. Our valuation model uses many indicators to compare Cara Therapeutic value to that of its competitors to determine the firm's financial worth. Cara Therapeutic is the top company in revenue category among its peers. It also is number one stock in gross profit category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cara Therapeutic's earnings, one of the primary drivers of an investment's value.Cara Revenue vs. Competition
Cara Therapeutic is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 60.94 Million. Cara Therapeutic totals roughly 20.97 Million in revenue claiming about 34% of equities under Health Care industry.
Cara Gross Profit vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Cara Therapeutic |
| = | 20.97 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Cara Therapeutic |
| = | (77.85 M) |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Cara Gross Profit Comparison
Cara Therapeutic is currently under evaluation in gross profit category among its peers.
Cara Therapeutic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cara Therapeutic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cara Therapeutic will eventually generate negative long term returns. The profitability progress is the general direction of Cara Therapeutic's change in net profit over the period of time. It can combine multiple indicators of Cara Therapeutic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.
Cara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cara Therapeutic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cara Therapeutic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cara Therapeutic's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Cara Therapeutic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Use Investing Themes to Complement your Cara Therapeutic position
In addition to having Cara Therapeutic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Yield ETFs Thematic Idea Now
High Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Yield ETFs theme has 106 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
To fully project Cara Therapeutic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cara Therapeutic at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cara Therapeutic's income statement, its balance sheet, and the statement of cash flows.